¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood group substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
¿µ¹® blood urea nitrogen ÇÑ±Û Ç÷¾×¿ä¼ÒÁú¼Ò
¼³¸í   
  ¿ä¼Ò´Â ¾Æ¹Ì³ë»êÀÇ Å»¾Æ¹Ì³ë¿¡ ÀÇÇØ »ý±ä ¾Ï³ë´Ï¾Æ¿Í Åº»ê°¡½º·ÎºÎÅÍ °£¿¡¼­ ÇÕ¼ºµÈ´Ù. Ç÷Áß¿¡¼­´Â Ç÷Àå°ú Ç÷±¸ÀÇ ¹°¼ººÐ ¾È¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Ù. Ç÷¾×¿ä¼ÒÁú¼Ò´Â ÄáÆÏÅ丮¿¡¼­ ¿©°úµÇ¸ç ÀϺΠ¿ä¼¼°ü¿¡¼­ ÀçÈí¼öµÇ°í, ³ª¸ÓÁö°¡ ¿ÀÁÜÁß¿¡ ¹è¼³µÈ´Ù. µû¶ó¼­ Ç÷¾×¿ä¼ÒÁú¼Ò´Â ÄáÆÏ±â´ÉÀÇ ÀúÇÏ¿¡ µû¶ó Áõ°¡µÇÁö¸¸, ½Ä»ç´Ü¹éÁú ¼·Ãë·®, Á¶Á÷ºØ±«, À§Àå°ü ÃâÇ÷ µî°ú Å»¼ö µî ¼øÈ¯Ç÷¾×·®ÀÇ ÀÌ»óÀ¸·Î º¯µ¿µÈ´Ù.
¿µ¹® blood product ÇÑ±Û Ç÷¾×Á¦Á¦
¼³¸í   
  1. »ç¶÷ÀÇ Ç÷¾×À» ¼ººÐº°·Î ºÐ¸®ÇÏ¿©, ±×°ÍÀ» ¿ø·á·Î Á¦Á¶ÇÑ ÀǾàǰ. ¾Ç¼º Á¾¾ç µûÀ§¿¡ ¼öÇ÷Çϴ ÀûÇ÷±¸, ¹éÇ÷º´-ÀÚ»ö¹Ýº´ÀÇ ÃâÇ÷À» ¸Ü°ÔÇϴ Ç÷¼ÒÆÇ, È­»óÀÇ Ä¡·á¿¡ ¾²´Â Ç÷Àå, »êÈÄ ÃâÇ÷À» ¸Ü°Ô Çϴ ¼¶À¯¼Ò¿ø µûÀ§°¡ ÀÖ´Ù. 2. »ç¶÷ÀÇ Ç÷¾×ÇüÀ» °Ë»çÇϴµ¥ ¾²´Â ¾à.
¿µ¹® blood urea nitrogen(BUN) ÇÑ±Û Ç÷Áß¿ä¼ÒÁú¼Ò
¼³¸í   
  Ç÷¾×¼ÓÀÇ ¿ä¼Ò¸¦ ¸»ÇÑ´Ù. ¿ä¼Ò¶õ ´Ü¹éÁúÀ̳ª ¾Æ¹Ì³ë»êÀÇ ÃÖÁ¾»ê¹°·Î½á °£¿¡¼­ »ý»êµÇ¾î ÄáÆÏÀ¸·Î ¹èÃâµÇ´Â ¹°ÁúÀÌ´Ù. À̰ÍÀº Àΰ£¿¡°Ô ¾ø¾î¼­´Â ¾ÈµÉ ´Ü¹éÁú°ú ¾Æ¹Ì³ë»êÀÇ »ê¹°À̹ǷΠ»ç¶÷¿¡°Õ ¾ðÁ¦³ª ÀÏÁ¤·®ÀÌ »ý»êµÈ´Ù. ÄáÆÏÀÇ ±â´ÉÀÌ ³ª»Ü °æ¿ì¿¡´Â À̰ÍÀÌ ÄáÆÏÀ¸·Î ¹è¼³µÇÁö ¸øÇÏ°í ¸ö¼Ó¿¡ ÃàÀûµÈ´Ù. ±×·¯¹Ç·Î ÄáÆÏÀÇ ±â´ÉÃøÁ¤¿¡ À̰ÍÀÌ À̿렵ȴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • end group
    ¸»´Ü±â
  • enteric group
    âÀÚ±Õ±º, Àå±Õ±º
  • functional group
    ÀÛ¿ë±â
  • glucophore group
    ´Ü¸À´Ü
  • group
    1. ±º, ¹«¸®, Áý´Ü 2. ±â 3. Á· 4. ±×·ì
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¼ú)
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • blood gas
    Ç÷¾×°¡½º
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood urea nitrogen
    Ç÷¾×¿ä¼ÒÁú¼Ò
  • blood pressure
    Ç÷¾Ð
  • blood product
    Ç÷¾×Á¦Á¦
  • portal blood pressure
    ¹®¸Æ¾Ð
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • blood sugar
    Ç÷´ç
  • blood supply
    Ç÷¾×°ø±Þ
  • blood test
    Ç÷¾×°Ë»ç
  • blood type
    Ç÷¾×Çü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • minority group
    ¼Ò¼öÁý´Ü
  • nonionic polar group
    ºñÀ̿±ؼº±â
  • open group
    °ø°³Áý´Ü, °³¹æÁý´Ü
  • osmophore group
    ¹ßÇâ´Ü
  • prosthetic group
    ¹èÇÕ±º
  • self-help group
    ÀÚÁ¶Áý´Ü
  • soluble group
    °¡¿ëÇØ±º
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • accelerans substance
    ÃËÁø¹°Áú
  • accessory food substance
    ºÎ¿µ¾ç¹°Áú
  • acrosomal substance
    ÷´Üü¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • posterior perforated substance ³ª substantia perforata posterior
    ÈÄÀ¯°øÁú(ý­êóÍîòõ).
  • posterior perforated substance ³ª substantia perforata posterior
    ÈÄÀ¯°øÁú(ý­êóÍîòõ).
  • pressor substance
    Ç÷¾Ð»ó½Â¹°Áú(¡­Úªòõ).
  • proper substance of cornea
    °¢¸·°íÀ¯Áú
  • proper substance of sclera
    °ø¸·°íÀ¯Áú
  • pyrogenic substance
    ¹ß¿­¹°Áú, ¹ß¿­ÀÎÀÚ.
  • pyrogenic substance
    ¹ß¿­¹°Áú(Û¡æðÚªòõ), ¹ß¿­ÀÎÀÚ(Û¡æðì×í­)
  • radiomimetic substance
    ¹æ»ç¼± À¯»çÀÛ¿ë¹°Áú
  • reaction substance
    ¹ÝÀÀ¹°Áú(ÚãëëÚªòõ).
  • red green visual substance
    Àû·Ï(»ö)½Ã°¢ ¹°Áú.
  • released substance
    ¹æÃâ¹°Áú(Û¯õóÚªòõ).
  • renal pressor substance
    ½Å½Â¾Ð¹°Áú(ãìã°äâÚªòõ).
  • BAC (blood alcohol concentration)
    Ç÷Áß¾ËÄڿóóµµ
  • BOLD(blood oxygenation level dependant)
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • BP=£¾blood pressure
    Ç÷¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Subacrosomal substance
    ÷´Üü¹Ø¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÇϹ°Áú
  • Subacrosomal substance
    ÷´Üü¹Ø¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÇÏÁú
  • Substance of synaptic cleft
    Æ´»õ¹°Áú
    [¿¾ ¿ë¾î] ¿­³»Áú
  • Osteoid substance
    Dz»À¹°Áú
    [¿¾ ¿ë¾î] °ñ¾çÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycosyl group
    ±Û¶óÀÌÄڽDZâ(Ðñ)
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
MBF medullary blood flow; muscle blood flow; myocardial blood flow
NRBC National Rare Blood Club; normal red blood cell; nucleated red blood cell
RBC red blood cell; red blood corpuscle; red blood count
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
125I-BHSP 125I-Bolton Hunter substance P
TBARS 2-thiobarbituric acid-reacting substance
AS Aggregation substance
CDS Clonidine displacing substance
DLS Digitalis-like substance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • pain producing substance
    µ¿Åë À¯¹ß ¹°Áú
  • psychoactive substance-induced organic mental disorder
    ȰÁ¤½Å¼º ¹°Áú·Î À¯µµµÈ ±âÁúÀû Á¤½Å Àå¾Ö
    ȰÁ¤½Å¼º ¹°ÁúÀÇ »ç¿ë°ú °ü·ÃµÈ ±âÁúÀû ³ú ÁõÈÄ. ¿­ °¡Áö Ư¼ö ÁõÈĸ¦ Æ÷ÇÔÇϰí Àִµ¥ Áßµ¶, Áß´Ü Áõ»ó, ¼¶¸Á, Ä¡¸Å, °Ç¸Á Àå¾Ö, ¸Á»ó Àå¾Ö, ȯ°¢, °¨Á¤ Àå¾Ö, Áö°¢ Àå¾Ö ¹× ÀÎ°Ý Àå¾Ö µîÀÌ´Ù. ¾ËÄÝ Áßµ¶°ú °°ÀÌ ¿øÀÎ ¹°ÁúÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸é À̸¦ ¸í±âÇÑ´Ù.
  • radioactive substance
    ¹æ»ç¼º ¹°Áú
  • receptive substance
    ¼ö¿ë ¹°Áú
    ±ÙÀ° Á¶Á÷, ƯÈ÷ ½Å°æÀÇ ¿îµ¿ Á¾ÆÇ ±Ùó¿¡ ÀÖÀ¸¸ç ÈïºÐÀ» ÀüµµÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ´Â ¹°Áú.
  • slow-reating substance
    Áö¹ÝÀÀ¼º ¹°Áú
    ¾î¶² ÆòȰ±ÙÀÇ ´À¸®°í Áö¼Ó¼ºÀÎ ¼öÃàÀ» ÀÏÀ¸Å°´Â ¾Æ³ªÇʶô½Ã ¹ÝÀÀ ½Ã¿¡ ¹æÃâµÇ´Â ¹°Áú ±âÈ£ SRS-A.
  • substance defect
    ¹°Áú °áÇÌ
  • substance P fiber
    P ¹°Áú ¼¶À¯
  • toxic substance
    À¯µ¶ ¼ººÐ, µ¶¹°
  • transmitter substance
    Àü´Þ ¹°Áú
  • white substance
    ¹é»ö Áú
  • arterial blood gas
    µ¿¸ÆÇ÷ °¡½º ºÐ¾Ð
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • artificial blood vessel
    Àΰø Ç÷°ü
  • autoimmune blood dyscrasia
    ÀÚ°¡ ¸é¿ª¼º Ç÷¾× ÀÌ»ó
  • autologous blood recovery system
    ÀÚ°¡ Ç÷¾× ȸº¹ ÀåÄ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
white substance <anatomy> Brain tissue composed of myelin-coated nerve cell fibres. White matter carries information between the nerve cells in the brain and spinal cord.
The inner portion of the cerebrum is composed of white matter.
See: grey matter.
(13 Nov 1997)
mullerian inhibiting substance A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin.
Synonym: mullerian inhibiting factor.
(05 Mar 2000)
muscular substance of prostate The smooth muscle in the stroma of the prostate.
Synonym: substantia muscularis prostatae, musculus prostaticus.
(05 Mar 2000)
controlled substance A substance subject to the Controlled Substances Act (1970), which regulates the prescribing and dispensing, as well as the manufacturing, storage, sale, or distribution of substance's assigned to five schedules according to their 1) potential for or evidence of abuse, 2) potential for psychic or physiologic dependence, 3) contributing a public health risk, 4) harmful pharmacologic effect, or 5) role as a precursor of other controlled substance's.
(05 Mar 2000)
cortical substance The superficial thin layer of compact bone.
Synonym: substantia corticalis, cortical substance.
(05 Mar 2000)
posterior perforated substance The bottom of the interpeduncular fossa at the base of the midbrain, extending from the anterior border of the pons forward to the mamillary bodies, and containing numerous openings for the passage of perforating branches of the posterior cerebral arteries.
Synonym: substantia perforata posterior, locus perforatus posticus, Malacarne's space.
(05 Mar 2000)
pressor substance One of several products of intestinal putrefaction believed to cause functional hypertension when absorbed, any alkaline substance that raises blood pressure.
Synonym: pressor amine, pressor substance.
(05 Mar 2000)
proper substance See: substantia propria of cornea, substantia propria membranae tympani, substantia propria sclerae.
(05 Mar 2000)
schwann's white substance <anatomy> The substance of the medullary sheath.
Source: Websters Dictionary
(01 Mar 1998)
psychoses, substance-induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance.
(12 Dec 1998)
sensitizing substance Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
h substance <haematology> A polysaccharide precursor molecule which is used to make the antigens on the surface of human blood cells that are classified in the ABO blood group system.
(09 Oct 1997)
slow-reacting substance Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules.
Compare: peptidyl leukotrienes.
Synonym: slow-reacting factor of anaphylaxis.
(05 Mar 2000)
slow reacting substance of anaphylaxis <immunology> Potent bronchoconstrictor and inflammatory agent released by mast cells, an important mediator of allergic bronchial asthma.
A mixture of three leukotrienes (LTC4 mainly, LTD4 and LTE4)
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • enxounter group
    (Á¤ÀÇ)Áý´Ü °¨¼ö¼º ÈÆ·Ã ±×·ì
  • ethnic group
    (»çȸ)ÀÎÁ¾ Áý´Ü
  • focus group
    Æ÷Ä¿½º ±×·ì(Å×½ºÆ®ÇÒ »óǰ¿¡ ´ëÇØ¼­ ÅäÀÇÇÏ´Â ¼ÒºñÀÚ ±×·ì)
  • fringe group
    ºñÁÖ·ùÆÄ
  • front group
    (À§ÀåÇÑ) Ç¥¸é»óÀÇ Á¶Á÷(´Üü)
  • ginger group
    (Á¤´ç µûÀ§ Á¶Á÷ ³»ºÎÀÇ)Çõ½ÅÆÄ
  • group
    ¹«¸®;ºñÇà ´ë´ë;ºñÇà ¿¬´ë
  • group
    ¸ðÀ¸(ÀÌ)´Ù;ºÐ·ùÇÏ´Ù
  • group captain
    °ø±º ´ë·É
  • group dynamics
    Áý´Ü ¿ªÇÐ
  • group grope
    È¥À½ ÆÄƼ;Áý´Ü Á¢ÃË
  • group insurance
    ´Üü º¸Çè
  • group marriage
    (¹Ì°³ ÀÎÁ¾ÀÇ) Áý´Ü °áÈ¥;ÀâÈ¥
  • group medicine
    =GROUP PRACTICE
  • group mind
    ±ºÁß ½É¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á